Does the eltrompobag treatment safe or effective for refractory chronic immune thrombocytopenia patients?
[ X ]
Tarih
2016
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
E-Century Publishing Corp
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Background: Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disorder characterized by immune-mediated platelet destruction and reduced platelet production. As the pathophysiology of the disease got clear, thrombopoietin receptor (TPO-R) agonists have been preferred in recent years, which seems to be an effective option in the treatment of resistant cases. Eltrombopag, a TPO-R agonist, is a second or third line medical treatment option for adults with chronic ITP. Objective: To determine the efficacy and safety of long-term eltrombopag treatment in treatment-refractory patients with primary ITP was the aim of this study. Materials and Methods: Retrospective data of 34 patients with refractory ITP who were treated with eltrombopag were examined. Efficacy and safety of the eltrombopag treatment was evaluated. Results: The total rate of response was 82%, and the median duration of response defined as the number of the platelets being over 50x10(9)/L was 14 (interquartile range: 7-28) days. In two patients, thrombosis was observed with no other additional risk factors due to or related to thrombosis. Conclusion: In spite of the fact that the responses to eltrombopag were satisfactory, patients need to be monitored closely for increasing platelet counts as well as thromboembolic events.
Açıklama
Anahtar Kelimeler
Immune Thrombocytopenia, Thrombopoietin Receptor Agonist, Thrombosis, Eltrombopag
Kaynak
International Journal of Clinical and Experimental Medicine
WoS Q Değeri
Q4
Scopus Q Değeri
N/A
Cilt
9
Sayı
9
